Michael Isaacman

mike

Nanometics LLC

Affiliations

New York University

Technologies

Therapeutic

Indication

Basic Research

Clinical Research

Clinical Trials

Drug Discovery

Oncology

Orphan Diseases

We are developing an enzyme inhibitor with pico-­‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-­‐negative breast cancer.

Newsletter Signup

Corporate Supporters

Community Service Providers